Dechert Secures Dismissal of FTC Antitrust Lawsuit Against Endo Pharmaceuticals Inc.
March 25, 2022
A Dechert antitrust/competition team led by partners George Gordon and Julia Chapman secured dismissal of an antitrust lawsuit brought against client Endo Pharmaceuticals Inc. by the Federal Trade Commission (FTC). In a sealed order, U.S. District Judge Royce C. Lamberth agreed to dismiss the case due to the FTC’s “failure to state a claim.”
The lawsuit, lodged in January 2021, stemmed from allegations that the terms of a 2017 license agreement settling a contract and patent dispute between Endo Pharmaceuticals and Impax Laboratories (now Amneal) violated Section 1 of the Sherman Act. In addition to seeking injunctive relief, the FTC’s complaint sought disgorgement of profits as a monetary remedy. The Court granted the motions to dismiss filed by Dechert, dismissing the FTC’s case in its entirety.
The Dechert team advising Endo also includes associates Forrest Lovett, John McClam and Eric Hageman.
About Dechert
Dechert is a leading global law firm with 22 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.
Related Professionals
